Patents by Inventor Stanley Wiegand
Stanley Wiegand has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220132818Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: October 20, 2021Publication date: May 5, 2022Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 11178860Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: October 21, 2019Date of Patent: November 23, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Publication number: 20200037587Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: October 21, 2019Publication date: February 6, 2020Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 10524458Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: July 2, 2018Date of Patent: January 7, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Patent number: 10492477Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: July 26, 2017Date of Patent: December 3, 2019Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
-
Publication number: 20180332833Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: July 2, 2018Publication date: November 22, 2018Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew J. Murphy
-
Publication number: 20170332611Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: July 26, 2017Publication date: November 23, 2017Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, Andrew Murphy
-
Patent number: 9795121Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: GrantFiled: May 4, 2015Date of Patent: October 24, 2017Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, John McWhirter, Andrew Murphy, Lynn Macdonald
-
Publication number: 20160120941Abstract: The invention provides methods of treating, inhibiting, or ameliorating a disease characterized by aberrant deposition of beta amyloid in a subject in need thereof, comprising administering to a subject a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the disease, or condition is treated, inhibited, or ameliorated, or wherein the onset or progression of the disease, or at least one symptom of the disease, is delayed. The IL-1 antagonist is an IL-1 trap, preferably comprising a sequence selected from the group consisting of SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28 and capable of binding and inhibiting IL-1. The therapeutic methods are useful for treating a human adult suffering from Alzheimer's Disease or cerebral amyloid angiopathy.Type: ApplicationFiled: May 30, 2014Publication date: May 5, 2016Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Susan D. Croll, Stanley Wiegand
-
Publication number: 20150313194Abstract: Non-human animals comprising a human or humanized C3 and/or C5 nucleic acid sequence are provided as well as methods for using the same to identify compounds capable of modulating the complement system. Non-human animals that comprise a replacement of the endogenous C5 gene and/or C3 gene with a human or humanized C5 gene and/or C3 gene, and methods for making and using the non-human animals, are described. Non-human animals comprising a human or humanized C5 gene under control of non-human C5 regulatory elements is also provided, including non-human animals that have a replacement of non-human C5-encoding sequence with human C5-encoding sequence at an endogenous non-human C5 locus. Non-human animals comprising a human or humanized C3 gene under control of non-human C3 regulatory elements is also provided, including non-human animals that have a replacement of non-human C3 protein-encoding sequence with human or humanized C3 protein-encoding sequence at an endogenous non-human C3 locus.Type: ApplicationFiled: May 4, 2015Publication date: November 5, 2015Inventors: Ying Hu, Adrianna Latuszek, Jingtai Cao, Alexander Mujica, Stanley Wiegand, John McWhirter, Andrew Murphy, Lynn Macdonald
-
Publication number: 20080085276Abstract: Methods of reducing or treating angiogenesis and/or inflammation associated with eye injury in a subject in need thereof, comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or ameliorating eye injury, particularly acute or subacute corneal injury and feature local administration (for example, subconjunctival injection or eye drops).Type: ApplicationFiled: November 30, 2007Publication date: April 10, 2008Inventors: Stanley Wiegand, Jingtai Cao
-
Patent number: 7300654Abstract: Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a high risk subject comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.Type: GrantFiled: January 19, 2005Date of Patent: November 27, 2007Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Stanley Wiegand, Jingtai Cao, Claus Cursiefen
-
Patent number: 7300653Abstract: Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a subject in need thereof comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.Type: GrantFiled: April 23, 2004Date of Patent: November 27, 2007Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Stanley Wiegand, Jingtai Cao, Claus Cursiefen
-
Publication number: 20060172944Abstract: Methods of reducing or treating angiogenesis and/or inflammation associated with eye injury in a subject in need thereof, comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or ameliorating eye injury, particularly acute or subacute corneal injury and feature local administration (for example, subconjunctival injection or eye drops).Type: ApplicationFiled: February 2, 2006Publication date: August 3, 2006Inventors: Stanley Wiegand, Jingtai Cao
-
Publication number: 20060123492Abstract: Methods for screening for agents capable of modulating human neuromedin U receptor 2 (NMUR2) activity are provided, as well as therapeutic methods for treating NMUR2-mediated conditions. More specifically, methods are provided for identifying agents capable of inhibiting NMUR2-mediated pain or nociception.Type: ApplicationFiled: January 13, 2006Publication date: June 8, 2006Inventors: Stanley Wiegand, Andrew Murphy, Susan Croll-Kalish, Richard Torres
-
Publication number: 20060058224Abstract: Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related conditions.Type: ApplicationFiled: September 15, 2005Publication date: March 16, 2006Inventors: George Yancopoulos, Stanley Wiegand, Mark Sleeman, Ellen-Marie Koehler-Stec
-
Publication number: 20060030529Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.Type: ApplicationFiled: September 1, 2005Publication date: February 9, 2006Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
-
Publication number: 20060024309Abstract: Methods of treating diabetes in mammals, particularly humans, by blocking or inhibiting VEGF-mediated activity. A preferred inhibitor of VEGF-mediated activity is a VEGF antagonist such as the VEGF fusion protein trap of SEQ ID NO:2 capable of binding and blocking VEGF. The method of the invention may be combined with other therapies, such as with insulin therapy.Type: ApplicationFiled: July 29, 2005Publication date: February 2, 2006Inventors: Jingtai Cao, Li-Hsien Wang, Hsin Lin, Mark Sleeman, Stanley Wiegand
-
Publication number: 20050260203Abstract: Modified chimeric polypeptides with improved pharmacokinetics and improved tissue penetration are disclosed useful for treating eye disorders, including age-related macular degeneration and diabetic retinopathy.Type: ApplicationFiled: March 25, 2005Publication date: November 24, 2005Inventors: Stanley Wiegand, Nicholas Papadopoulos, George Yancopoulos, James Fandl, Thomas Daly
-
Publication number: 20050197291Abstract: Methods of preventing, reducing, or treating corneal transplant rejection to improve transplant survival in a high risk subject comprising administering an agent capable of blocking or inhibiting vascular endothelial growth factor (VEGF) are provided. The methods are useful for inhibiting or preventing corneal transplant rejection in a human subject who is the recipient of a transplanted cornea.Type: ApplicationFiled: January 19, 2005Publication date: September 8, 2005Inventors: Stanley Wiegand, Jingtai Cao, Claus Cursiefen